SCHEMBL13557432

SCHEMBL13557432

COc1cc2c(cc1CO)OCC1Oc3c(cc([N+](=O)[O-])c4c3C=CC(C)(C)O4)C(=O)C21

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 11/20 0.58
▸ MAPT P10636 8/20 0.58
▸ SMN1; SMN2 Q16637 8/20 0.58
▸ TP53 P04637 4/20 0.58
▸ CYP2C19 P33261 4/20 0.58
▸ TSHR P16473 3/20 0.58
▸ CYP1A2 P05177 2/20 0.58
▸ HSP90AA1 P07900 2/20 0.58
▸ CYP2D6 P10635 1/20 0.58
▸ TDP1 Q9NUW8 5/20 0.54
▸ ALDH1A1 P00352 5/20 0.54
▸ KDM4E B2RXH2 5/20 0.54
▸ USP2 O75604 4/20 0.54
▸ MAPK1 P28482 4/20 0.54
▸ HPGD P15428 2/20 0.43
▸ LMNA P02545 4/20 0.42
▸ THRB P10828 1/20 0.42
▸ ALOX15 P16050 1/20 0.42
▸ HSD17B10 Q99714 1/20 0.42
▸ MEN1 O00255 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13557427 1.00 CYP3A4 (0.58) CYP3A4MAPTSMN1; SMN2TP53CYP2C19
SCHEMBL11938545 0.91 CYP3A4 (0.69) CYP3A4MAPTSMN1; SMN2TP53CYP2C19
SCHEMBL11938552 0.91 CYP3A4 (0.69) CYP3A4MAPTSMN1; SMN2TP53CYP2C19
SCHEMBL13557431 0.89 CYP3A4 (0.61) CYP3A4MAPTSMN1; SMN2TP53CYP2C19
SCHEMBL13557428 0.87 CYP3A4 (0.66) CYP3A4MAPTSMN1; SMN2TP53CYP2C19
SCHEMBL13557430 0.87 CYP3A4 (0.66) CYP3A4MAPTSMN1; SMN2TP53CYP2C19
SCHEMBL13557397 0.84 CYP3A4 (0.82) CYP3A4MAPTSMN1; SMN2TP53CYP2C19
SCHEMBL11938551 0.79 CYP3A4 (0.74) CYP3A4MAPTSMN1; SMN2TP53CYP2C19
SCHEMBL13557353 0.79 CYP3A4 (0.74) CYP3A4MAPTSMN1; SMN2TP53CYP2C19
SCHEMBL13557429 0.79 CYP3A4 (0.70) CYP3A4MAPTSMN1; SMN2TP53CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180009763-A1 CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING LANTHEUS MEDICAL IMAGING, INC. (US) 2018-01-11 — — US disclosed
US-9718786-B2 Contrast agents for myocardial perfusion imaging LANTHEUS MEDICAL IMAGING, INC. (US) 2017-08-01 — — US disclosed
US-20160130235-A1 CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING LANTHEUS MEDICAL IMAGING, INC. (US) 2016-05-12 — — US disclosed
US-9161997-B2 Contrast agents for myocardial perfusion imaging LANTHEUS MEDICAL IMAGING, INC. 2015-10-20 — — US disclosed
US-20120276006-A1 CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING LANTHEUS MEDICAL IMAGING, INC. (US) 2012-11-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180009763-A1 CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING TNNI3, TNNT2, FABP3 CYP3A4 3831/4885MAPT 4043/4885SMN1; SMN2 2969/4885
US-20160130235-A1 CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING TNNI3, TNNT2, FABP3 CYP3A4 3831/4885MAPT 4043/4885SMN1; SMN2 2969/4885
US-20120276006-A1 CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING TNNI3, TNNT2, FABP3 CYP3A4 3831/4885MAPT 4043/4885SMN1; SMN2 2969/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback